-transparent.png){kind=logo}
N-(Phosphonoacetyl)-L-aspartate (PALA) is a synthetic antimetabolite exhibiting striking oncolytic properties against a wide variety of experimental solid tumors. The clinical dose-limiting factor is mucocutaneous toxicity which is reversible and dose-related. Delineation of the single-agent activity of PALA in human cancer must still await results of recently activated trials.
Related Publications
M Rozencweig, and
R Abele, and
M Piccart, and
D D Von Hoff, and
F M Muggia
January 1979,
Cancer chemotherapy and pharmacology,
M Rozencweig, and
R Abele, and
M Piccart, and
D D Von Hoff, and
F M Muggia
November 1981,
European journal of cancer & clinical oncology,
M Rozencweig, and
R Abele, and
M Piccart, and
D D Von Hoff, and
F M Muggia
August 1979,
Cancer treatment reports,
M Rozencweig, and
R Abele, and
M Piccart, and
D D Von Hoff, and
F M Muggia
January 1980,
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
M Rozencweig, and
R Abele, and
M Piccart, and
D D Von Hoff, and
F M Muggia
January 1980,
Cancer treatment reports,
M Rozencweig, and
R Abele, and
M Piccart, and
D D Von Hoff, and
F M Muggia
January 1979,
Cancer treatment reports,
M Rozencweig, and
R Abele, and
M Piccart, and
D D Von Hoff, and
F M Muggia
October 1993,
Pharmaceutical research,
M Rozencweig, and
R Abele, and
M Piccart, and
D D Von Hoff, and
F M Muggia
January 1980,
Cancer treatment reports,
M Rozencweig, and
R Abele, and
M Piccart, and
D D Von Hoff, and
F M Muggia
December 1991,
Annals of internal medicine,
M Rozencweig, and
R Abele, and
M Piccart, and
D D Von Hoff, and
F M Muggia
January 1979,
Cancer treatment reports,
